# Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

> **NCT03179930** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 47 (actual)

## Conditions studied

- Lymphoma
- Relapsed
- Refractory

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03179930
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-06-07
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-07-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03179930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03179930, "Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03179930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*